What Johnson & Johnson's Quarter ended Sep 27, 2026 10-Q says: 8 signals
Johnson & Johnson filed its latest 10-Q with the SEC on Oct 21, 2026. It discusses acquisition completed, digital transformation and goodwill impairment.
Get Johnson & Johnson's live signals in Claude or ChatGPT, or by API
What changed at Johnson & Johnson this week? Use Autobound signals for jnj.com.- Filed
- Oct 21, 2026
- Period
- Quarter ended Sep 27, 2026
- Filings
- 3
- Signals
- 30
Source: Autobound Signal API · 86 signals tracked for Johnson & Johnson · updated
10-Q · latest 10
What Johnson & Johnson's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 27, 2026
Filed · 8 signals
Recorded $5.5 billion charge for proposed talc ovarian litigation resolution
Johnson & Johnson recorded a charge of approximately $5.5 billion in Q3 and the fiscal nine months of 2026 related to the proposed talc ovarian litigation resolution.
$5.5B
charge related to proposed talc ovarian litigation resolution
Johnson & Johnson plans to separate Orthopaedics business by mid-2027
The Company announced its intention to separate its Orthopaedics business and expects the separation to be completed in mid-2027.
The Company is executing a multi-year, enterprise-wide initiative to standardize and simplify systems across human resources, IT, procurement, supply chain, and finance functions to support financial shared services capabilities.
financial systems
J&J records $1.0 billion IPR&D charge for Firefly Bio acquisition
Johnson & Johnson incurred an acquired in-process research and development expense of approximately $1.0 billion related to the acquisition of Firefly Bio, Inc.
$1B
acquired in-process research and development expense related to the acquisition of Firefly Bio, Inc.
Recorded $0.4 billion impairment charge for non-strategic PreCardia asset
The company recorded an in-process research and development impairment charge of approximately $0.4 billion in the fiscal nine months of 2026, primarily related to PreCardia.
$400M
charge primarily related to PreCardia asset impairment
Pre-tax margin compressed significantly to 0.1% of sales in Q3 2026
Consolidated earnings before provision for taxes dropped to $34.0 million (0.1% of sales) in Q3 2026 from $7.5 billion (31.2% of sales) in Q3 2025, driven by litigation and acquired IPR&D charges.
$34M
earnings before provision for taxes on income in Q3 2026
0.1%
earnings before provision for taxes on income as a percent of sales in Q3 2026
International sales grew 6.2% to $31.9 billion in fiscal nine months 2026
Sales by international companies reached $31.9 billion for the fiscal nine months, up 6.2% total with operational growth of 3.0%.
$31.9B
sales by international companies in the fiscal nine months of 2026
6.2%
increase in international company sales compared to prior year
- SEC EDGAR
10-Q
Filed · 10 signals
JNJ is executing three major restructuring programs to streamline operations, exit non-strategic markets and product lines, and optimize its manufacturing footprint.
$2.4B
Total estimated costs for three major restructuring programs across Innovative Medicine ($700M), Surgery ($650M), and Orthopaedics ($1000M) segments, using...
generic and biosimilar manufacturers
The company is undergoing a major digital transformation to integrate and simplify core business processes and systems across the enterprise.
J&J initiates $750M supply chain restructuring, adding to $1.7B in ongoing programs
The company is overhauling its Innovative Medicine supply chain, MedTech Surgery franchise, and Orthopaedics franchise, with total costs exceeding $2.4B.
$750M
Estimated cost for new Innovative Medicine supply chain restructuring program
Earlier 10-Q filings
- 10-QFiled · 12 signalsSEC EDGAR
Showing 10 of 30 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Johnson & Johnson earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| In 'full launch mode' for new $5B+ blockbuster bladder cancer drugThe company is executing a major launch for Inlexo, a transformative bladder cancer treatment projected to be a $5 billion+ asset. This signals massive investment in sales, marketing, supply chain, and physician education to support the rollout. | |
| Facing significant headwind from STELARA biosimilar competitionThe loss of exclusivity for STELARA is a major competitive and financial headwind, creating pressure to offset revenue loss. This pressure is the primary driver for J&J's aggressive investment in new blockbuster drugs and high-growth MedTech areas to fuel its 'new era of growth'. | |
| Actively pursuing small, strategic acquisitions after 60+ recent dealsThe CFO highlighted a strategy of executing numerous smaller, high-value acquisitions (over 60 in the last two years) rather than large, speculative ones. This indicates they are constantly evaluating and integrating new technologies and companies, creating opportunities for M&A advisory, IT integration, and other related services. | |
| Sustaining massive R&D investment at $3.7 billion in Q3The company continues to invest heavily in innovation, spending $3.7 billion on R&D in a single quarter, representing 15% of sales. This massive, ongoing budget creates significant opportunities for suppliers of research technologies, lab equipment, data analytics, and clinical trial services. | |
| Gaining significant market share across multiple key drug franchisesThe company is successfully growing market share for key products like DARZALEX (multiple myeloma) and TREMFYA (IBD), which grew 40%. This success validates their commercial strategy and indicates they will continue to fund the sales and marketing teams and technologies that are driving these gains. | |
| Navigating high-stakes talc litigation and legal challengesThe company is actively managing ongoing talc litigation, a significant legal and financial issue. The CFO highlighted the upcoming Daubert motions as a key judicial process, indicating this remains a top-level concern that can influence spending on legal tech, risk management, and compliance solutions. |
Signal API · MCP
Track Johnson & Johnson with the Signal API
One POST /v1/companies/enrich call with jnj.com returns Johnson & Johnson 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"jnj.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Johnson & Johnson 10-Q
When did Johnson & Johnson file its latest 10-Q?
What did Johnson & Johnson disclose in its latest 10-Q?
What did Johnson & Johnson say on its recent earnings calls?
Where can I read Johnson & Johnson's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .